SNGX

+ Watchlist + Portfolio

Soligenix, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.38
52-Week Range: $0.28 – $3.72
Market Cap: $8.27M
P/E (TTM): —
EPS (TTM): -0.72
Dividend Yield: —

Advanced Metrics

Price/Book: 1.24
PEG Ratio: —
Return on Equity: -241.65%
Return on Assets: -84.87%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 2.77
Debt/Equity: 0.05
Total Debt: $302.59K
Free Cash Flow: $-6.28M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-1.21M

SNGX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$250.00K	$0.00	$0.00	$0.00
Cost of Revenue	$550.82K	$742.05K	$119.37K	$0.00
Gross Profit	-$300.82K	-$742.05K	-$119.37K	$0.00
Research & Development	$7.94M	$3.31M	$5.22M	$7.49M
Selling, General & Admin	$6.69M	$4.48M	$4.22M	$4.36M
Operating Expenses	$13.81M	$6.93M	$9.35M	$11.85M
Operating Income	-$14.11M	-$7.67M	-$9.46M	-$11.85M
EBITDA	-$14.11M	-$7.67M	-$9.46M	-$11.84M
Pretax Income	-$14.95M	-$7.91M	-$8.68M	-$11.59M
Income Tax	-$1.15M	-$1.77M	-$409.11K	-$506.62K
Net Income	-$13.80M	-$6.14M	-$8.27M	-$11.08M
Diluted EPS	-76.96	-12.66	-4.98	-2.14
Diluted Shares	179459	484995	1.66M	5.19M

SNGX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$13.36M	$8.45M	$7.82M	$7.94M
Receivables	$219.33K	$195.15K	$0.00	—
Current Assets	$13.85M	$9.51M	$8.83M	$8.85M
Total Assets	$14.28M	$9.80M	$8.97M	$9.24M
Current Liabilities	$16.52M	$6.15M	$4.85M	$3.70M
Long-Term Debt	—	$1.01M	—	—
Total Debt	$10.24M	$3.49M	$1.48M	$358.14K
Total Liabilities	$16.75M	$7.27M	$4.85M	$3.94M
Retained Earnings	-$219.56M	-$225.70M	-$233.97M	-$245.05M
Shareholders' Equity	-$2.47M	$2.52M	$4.12M	$5.29M
Working Capital	-$2.66M	$3.36M	$3.98M	$5.15M

SNGX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$12.65M	-$8.60M	-$8.40M	-$10.27M
Capital Expenditure	-$13.07K	—	—	-$5.88K
Free Cash Flow	-$12.66M	-$8.60M	-$8.40M	-$10.27M
Depreciation & Amortisation	$24.56K	$6.55K	$5.81K	$3.22K
Stock-Based Compensation	$333.39K	$370.18K	$329.81K	$587.58K
Investing Cash Flow	-$13.07K	$0.00	$0.00	-$5.88K
Financing Cash Flow	$76.82K	$3.66M	$7.76M	$10.39M
Net Change in Cash	-$12.59M	-$4.94M	-$641.53K	$116.64K

SNGX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Cost of Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Gross Profit	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.94M	$1.68M	$1.58M	$2.28M	$1.78M
Selling, General & Admin	$1.08M	$1.09M	$996.60K	$1.19M	$1.10M
Operating Expenses	$3.03M	$2.76M	$2.58M	$3.47M	$2.88M
Operating Income	-$3.03M	-$2.76M	-$2.58M	-$3.47M	-$2.88M
EBITDA	-$3.03M	-$2.76M	-$2.58M	-$3.47M	-$2.88M
Pretax Income	-$2.95M	-$2.70M	-$2.53M	-$3.40M	-$2.82M
Net Income	-$2.95M	-$2.70M	-$2.53M	-$2.90M	-$2.82M
Diluted EPS	-0.97	-0.82	-0.58	—	-0.28
Diluted Shares	3.05M	3.28M	4.33M	—	10.16M

SNGX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$7.30M	$5.10M	$10.53M	$7.94M	$6.03M
Current Assets	$7.64M	$5.32M	$10.88M	$8.85M	$6.57M
Total Assets	$7.75M	$5.76M	$11.29M	$9.24M	$6.92M
Current Liabilities	$4.13M	$3.63M	$3.42M	$3.70M	$3.62M
Total Debt	$79.13K	$411.40K	$385.05K	$358.14K	$330.66K
Total Liabilities	$4.13M	$3.93M	$3.70M	$3.94M	$3.83M
Retained Earnings	-$237.21M	-$239.62M	-$242.15M	-$245.05M	-$247.88M
Shareholders' Equity	$3.61M	$1.83M	$7.60M	$5.29M	$3.09M
Working Capital	$3.51M	$1.69M	$7.46M	$5.15M	$2.95M

SNGX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$1.85M	-$2.74M	-$2.93M	-$2.75M	-$2.36M
Capital Expenditure	—	—	-$608.00	-$1.96K	—
Free Cash Flow	-$1.85M	-$2.75M	-$2.93M	-$2.75M	-$2.36M
Depreciation & Amortisation	$608.00	$703.00	$911.00	$1.00K	$1.10K
Stock-Based Compensation	$63.60K	$99.51K	$104.35K	$320.13K	$121.21K
Investing Cash Flow	—	—	-$608.00	-$1.96K	—
Financing Cash Flow	$1.32M	$545.63K	$8.36M	$157.88K	$451.00K
Net Change in Cash	-$522.34K	-$2.20M	$5.43M	-$2.59M	-$1.91M

Market Snapshot

About

Soligenix is a late-stage biopharmaceutical company focused on developing products to treat rare diseases where there is an unmet medical need. The company has active programs in fibrosis and inflammation, vaccines, and oncology. Soligenix is advancing multiple clinical-stage product candidates including treatments for gastrointestinal diseases and biodefense countermeasures.